Literature DB >> 8913979

Maternal-fetal glucose metabolism and fetal growth retardation. Is there an association?

J M Piper1, N T Field, K Higby, B D Elliott, O Langer.   

Abstract

OBJECTIVE: To test the hypothesis that in normotensive pregnancies decreased maternal glucose response leads to relative fetal hypoglycemia and hypoinsulinemia, which result in delayed fetal growth. STUDY
DESIGN: We enrolled patients with and without risk factors for growth retardation. Each underwent an oral glucose tolerance test with both glucose and insulin evaluation. Cord blood was obtained for glucose and insulin evaluation.
RESULTS: The normotensive pregnancies at risk had lower maternal glucose levels (index, 91 vs. 116 mg/dL; P < .05), a trend toward lower maternal insulin levels (index, 398 vs. 483 muIU/mL; P = NS) and normal maternal insulin/glucose ratios. We found no differences, however, in the fetal metabolic parameters (glucose 83 vs. 78 mg/dL, insulin 17 vs. 24 muIU/mL; P = NS).
CONCLUSION: Maternal glucose metabolism is altered in nonhypertensive pregnancies, with a risk of delayed fetal growth; however, the fetal glucose response may remain normal in the face of fetal growth retardation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913979

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  The obstetric and neonatal implications of a low value on the 50-g glucose screening test.

Authors:  Kimberly K Ma; Lisa Mele; Mark B Landon; Catherine Y Spong; Susan M Ramin; Brian Casey; Ronald J Wapner; Michael W Varner; Dwight J Rouse; John M Thorp; Anthony Sciscione; Patrick Catalano; Margaret Harper; George Saade; Steve N Caritis; Yoram Sorokin; Alan M Peaceman
Journal:  Am J Perinatol       Date:  2012-12-27       Impact factor: 1.862

2.  Does hypoglycemia following a glucose challenge test identify a high risk pregnancy?

Authors:  Suzanne K Pugh; Dorota A Doherty; Everett F Magann; Suneet P Chauhan; James B Hill; John C Morrison
Journal:  Reprod Health       Date:  2009-07-14       Impact factor: 3.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.